Sutro Biopharma, Inc. (STRO) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank
May 14, 2024 4:12 PM EDTDeutsche Bank analyst James Shin lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $10.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "We're updating our STRO model for 1Q24 results, maintaining our Buy rating and lowering our price target to... More
Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO)
May 14, 2024 8:25 AM EDTWedbush analyst David Nierengarten reiterated an Outperform rating and $8.00 price target on Sutro Biopharma (NASDAQ: STRO)
The analyst comments "STRO reported 1Q24 earnings. The company continues to advance lead asset luvelta (FolR-targeted ADC) through multiple clinical studies. Part 1 of the registration-directed REFRaME-01 study in... More
